• Managing Myeloma ASH 2013 Meeting Highlights - Coming Soon!
  • FAQ's

    FAQ Library

    Respected thought leaders answer frequently asked questions on issues important to your practice – available in video, audio, and transcript formats.

  • FAQ's

    Meeting Highlights

    Video and written highlights from major annual meetings regarding the most current multiple myeloma clinical study findings–one of our most popular features!

  • FAQ's

    CE Activities

    Accredited activities that focus on the assessment, diagnosis and treatment of multiple myeloma. Each activity highlights clinically relevant, timely and accurate scientific information, designed to support you in your search for additional education and improved patient care.

  • Recognizing the Signs and Symptoms of Multiple Myeloma in the Primary Care Setting

What's New

Clinical Expert Commentary
Historical Overview of Multiple Myeloma Therapy
Robert Kyle, MD
Annual Meeting Highlights
ASH 2013: Highlights in Multiple Myeloma
Philip McCarthy, MD – Moderator; Kenneth Anderson, MD; Thierry Facon, MD; Antonio Palumbo, MD; and Koen van Besien, MD, PhD
CE Activity
How Long Should I Continue Maintenance Therapy?
Marie Sabo Recine, MS, and Eugene R. Tombler, PhD – Contributing authorsD
CE Activity
Managing Relapsed/Refractory Myeloma: Seven Questions that Guide Practice Today
Joseph R. Mikhael, MD
CE Activity
Is This Multiple Myeloma?
Parameswaran Hari, MD
CE Activity
ASCO 2013: Emerging Immunotherapies
Kenneth C. Anderson, MD and Sagar Lonial, MD
FAQ Library
What is oprozomib?
Benyam Muluneh, PharmD, BCOP, CPP
Clinical Trials
Highlighted Trials 2013: Phase II Trial with Elotuzumab Plus Lenalidomide and Low-Dose Dexamethasone in the RR Setting
Clinical Trials
Highlighted Trials 2013: A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone in Relapsed/Refractory Patients